H.C. Wainwright Maintains Buy Rating on Insmed with $120 Price Target

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed with a $120.00 price target. Fein has a 5-star rating and a 10.1% average return. The company reported Q1 revenue of $92.82 million and a GAAP net loss of $256.58 million. Corporate insider sentiment is negative, with an increase in insiders selling their shares.

Insmed Incorporated (NASDAQ: INSM) reported its second-quarter 2025 earnings, revealing a net loss of $322 million, but the company's shares surged by 68% over the past quarter. This significant gain is attributed to confirmed guidance for Global ARIKAYCE revenue growth and the company's inclusion in multiple Russell indices [1].

Despite the quarterly net loss, Insmed's ARIKAYCE revenue reached $107.4 million, a 19% increase year-over-year, surpassing analyst estimates of $103.03 million [3]. The company's strong performance in the U.S. market, with a 7.7% year-over-year increase, and impressive growth in international markets, particularly Japan and Europe, contributed to this revenue growth.

The company's late-stage pipeline developments also boosted investor confidence. Insmed highlighted progress with brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP), with the U.S. launch of brensocatib for non-cystic fibrosis bronchiectasis (NCFB) scheduled for Q3 2025. Additionally, the Phase 2b study of TPIP in pulmonary arterial hypertension (PAH) showed promising results, with a 35% reduction in pulmonary vascular resistance (PVR) and a 35.5-meter improvement in 6-minute walk distance (6MWD) [1].

However, Insmed's operating expenses increased significantly, leading to a widened operating loss. R&D expenses rose to $177.2 million, and SG&A expenses jumped to $154.8 million. Despite these increased investments, the company maintains a robust capital position with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2025 [1].

Investors remain optimistic about Insmed's future prospects, with the company's total return of 308.60% over three years. The upcoming launch of brensocatib in the U.S. and favorable market response to ARIKAYCE are expected to bolster revenue projections. Insmed's commitment to expanding its impact on patients through innovative therapies continues to be a focal point of its business strategy.

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed with a $120.00 price target. Fein has a 5-star rating and a 10.1% average return. The company reported Q1 revenue of $92.82 million and a GAAP net loss of $256.58 million. Corporate insider sentiment is negative, with an increase in insiders selling their shares [2].

References:
[1] https://www.investing.com/news/company-news/insmed-q2-2025-slides-reveal-19-revenue-growth-amid-clinical-pipeline-advances-93CH-4176654
[2] https://www.marketbeat.com/instant-alerts/insmed-nasdaqinsm-hits-new-1-year-high-heres-what-happened-2025-08-05/
[3] https://www.gurufocus.com/news/3044140/insmed-inc-insm-surpasses-q2-2025-revenue-estimates-with-1074-million-eps-details-awaited